Effect of beta-blockers on the mortality of Japanese patients with myocardial infarction

Clinical outcome after acute coronary syndrome in Japanese patients: An observational cohort study

“…In contrast, in this study patients with STEMI and NSTE-ACS received betablocker in 57.1% and 38.0% of cases, respectively, suggesting that vasospastic angina is more common in Japan, especially after MI and attending physicians might prescribe betablockers only for patients who were expected to develop left ventricular remodeling [19]. Meanwhile, some studies showed that beta-blockers improved survival in Japanese patients after MI regardless of high frequency of vasospastic angina [20,21]. Furthermore, ACE inhibitor or angiotensin receptor blocker (ARB) was taken in about 40% of NSTE-ACS patients and 70% of STEMI patients, whereas statin treatment was received in around 50% in the present study.…”

The Relationship between Paroxysmal Atrial Fibrillation and Coronary Artery Spasm

“…Five patients underwent the provocation test under administration of β ‐blockers, and coronary artery spasm was induced in four of the patients in the AF group. It has been reported that nonselective β ‐blockers worsened coronary artery spasm and prognosis, but that β ‐1 selective β ‐blockers were effective in preventing coronary artery spasm . In our study, all five patients who received β ‐blockers were administrered β ‐1 selective β ‐blockers.…”

“…It has been reported that nonselective β-blockers worsened coronary artery spasm and prognosis, 31,32 but that β-1 selective β-blockers were effective in preventing coronary artery spasm. [33][34][35][36][37][38] In our study, all five patients who received β-blockers were administrered β-1 selective β-blockers.…”

Long-Term Effect of β-Blocker Use on Clinical Outcomes in Postmyocardial Infarction Patients: A Systematic Review and Meta-Analysis

“…Supplementary Figure S1 illustrated the selection process. This study included 22 retrospective studies (9, 10, 13, 17-20, 22, 24-30, 33-38, 40) (including 1,73,438 β-blocker users and 31,836 no β-blocker users) and 7 prospective studies (11,12,21,23,31,32,39) (including 22,557 β-blocker users and 14,182 no β-blocker users). Among the included studies, 24 studies (9-13, 19, 21-25, 27-38, 40) (including 1,81,757 β-blocker users and 37,695 no β-blocker users) were included to explore the long-term effect of β-blocker use on all-cause mortality in patients after MI.…”